Objective: African American (AA) health is seriously threatened by unremitting epidemics of diabetes and cardiovascular disease (CVD). However, the role of metabolic syndrome (MetS) in the AA population has not been investigated widely. This study examined the prevalence of MetS and assessed its cross-sectional relationship to CVD in Jackson Heart Study (JHS) cohort.
ardiovascular diseases (CVD) and diabetes are the most common cause of death and disability in the United States and in most developed countries. In the US, African Americans suffer from CVD significantly earlier, more often and experience poorer outcomes than their European American counterparts (1, 2) . African-Americans also have not shared equally in the well-documented national declines in CVD mortality of the past decades (3) . Differences in prevalence rates of conventional risk factors, as well as socioeconomic factors have been proposed as key elements of the disparities, but are not fully explanatory (4) (5, 6) . While there have been many reports describing the existence of these disparate patterns of CVD, epidemiological study data on factors responsible for these marked differences are limited. Much of the available data relating CVD risk factors has come from predominantly white populations (7) (8) (9) .
The metabolic syndrome (MetS), a concurrence of several readily measured cardiometabolic characteristics, has become a subject of great interest. It is tightly associated with three major disease epidemics in the US: obesity, type 2 diabetes mellitus (T2DM), and continued high rates of CVD (8, 9) . According to the definition from the National Cholesterol Education Program's Third Adult Treatment Panel Report (NCEP/ATP III), MetS can be defined when three or more metabolic disorders, including abdominal obesity, elevated plasma triglyceride concentration, low plasma highdensity lipoprotein cholesterol (HDL-C) concentration, elevated blood pressure and elevated fasting glucose, are present (10). Ford et al (11, 12) reported that the prevalence of MetS among US adults was significantly increased from 23.1% to nearly 27% during the 1990's decade. They also noted distinct patterns of cardiometabolic risk factors among different ethnic groups in the NHANES sample. For instance, AfricanAmerican men had the highest age-adjusted prevalence of hypertension and AfricanAmerican women had the highest prevalence of abdominal obesity. Since MetS is a significant precursor of CVD (13) , the racial/ethnic differences in characteristics and prevalence of MetS may help explain some of the ethnic disparity in development of CVD, however, limited information is currently available on the ethnic-specific prevalence of the MetS and the associated prevalence of CVD in AA population. This study examines the prevalence of MetS, and assesses its association with CVD in Jackson Heart Study, a large all-African American populationbased cohort drawn from metropolitan Jackson, Mississippi---the most densely populated region of the state with the highest prevalence of CVD in the nation.
RESEARCH DESIGN AND METHODS
The JHS is a prospective population-based investigation of the predictors and outcomes of CVD and related disorders among AfricanAmericans. The original design and sampling plan for the JHS included only those aged 35-84 years old, which have been described in detail previously (14) . The current JHS cohort comprises 5302 participants in total, consisting of 5036 adults aged 35-84 years old, and an additional 251 aged 21-34 and 15 aged > 85. The latter group entered the study as part of the nested JHS Family Study (15, 16 Samples of glucose and lipids were collected according to standardized procedures and processed at the Central Laboratory (University of Minnesota) described in previous publication (14, 15) . Sitting blood pressure was measured twice at 5-minutes intervals; the average of two measurements was used for analysis. Two measures of the waist (at the level of the umbilicus, in the upright position) were averaged to determine baseline waist circumference for each participant. For the present analysis, we excluded individuals who did not complete data collection on any components of MetS. Criteria for the Metabolic Syndrome. The ATP III has identified five components of MetS that related to CVD (Abdominal obesity, High triglyceride concentration and Low HDL-C concentration, elevated blood pressure, elevated fasting glucose concentration) (10) . In consonance with the ATP III definition, the subjects were considered to have the MetS if they had 3 or more of following: 1) Abdominal obesity, defined by waist circumference ≥102 cm (40 inches) in men and ≥88 cm (35 inches) in women; 2) Elevated blood pressure, defined as a systolic blood pressure of 130 mmHg or greater and/or a diastolic blood pressure of 85 mmHg or greater, physician diagnosis and/or use of antihypertensive drugs; 3) Elevated plasma triglyceride concentration (≥ 150 mg/dL) or treated fibrate medication; 4) Low HDL-C concentration (men < 40 mg/dL and women < 50 mg/dL); and 5) Elevated fasting glucose concentration (≥ 100 mg/dL) or diagnosed T2DM. Only individuals who contributed fasting blood specimens, with exception of those under treatment for T2DM, were included in this report. Definition of coronary heart disease, Cerebrovascular disease and CVD. Prevalent coronary heart disease (CHD) was defined as evidence of a previous myocardial infarction by ECG based on Minnesota Code criteria (Codes 1.1 and 1.2 plus 4.1-4.2, or 5.1-5.2) or history of physician-diagnosed myocardial infarction or either of the following: percutaneous coronary intervention or coronary bypass surgery. Cerebrovascular disease (CBD) was defined as history of CBD (by personal history, CBD signs and symptoms ascertained by standardized questionnaires), transient ischemic attack or carotid endarterectomy and/or angioplasty. CVD was defined as having either CHD or CBD. All medical history obtained at baseline was self-reported. Reference Group. To determine the crosssectional association of MetS with morbid vascular conditions, we calculated the odds of prevalent cardiovascular disease manifestations (CHD, CBD and CVD) in those with MetS, compared to reference group, defined as participants who did not have MetS. Education, Annual Income, Alcohol and Smoking. Educational attainment was divided into four categories: < HS (less than high school education); HS or GED; > HS but < College and College or greater. Annual incomes were divided into five categories according to the participant's household income for the previous year: < $16,000; $16,000 to 24,999; $25000 to 49,999; $50,000 to 99,999 and more than $100,000. Alcohol consumption and cigarette smoking was analyzed as current practice (self reported as user in past 12 months versus nonuser).
STATISTICAL METHODS
Data were analyzed using the SAS© system for Windows, version 9.1 (SAS Institute, Cary NC, 2004). Contingency tables were compiled to calculate the sample prevalence of MetS and its possible components (elevated blood pressure, abdominal obesity, low HDL-C, elevated glucose and triglyceride concentration). Prevalence was calculated separately for age, sex, current alcohol consumption and smoking status, marital status, education, annual household income. The chi-square test was performed to assess the significance of subgroup differences.
To assess the prevalence of each metabolic component, age-and sex-specific prevalence for each metabolic component was calculated separately from entire JHS cohort. Logistic regression models were used to calculate odds ratios (OR) and their 95% confidence intervals (CI) to assess the odds of CVD, CHD and CBD being present in a participant with MetS vs. a participant without MetS. Statistical tests of hypothesis with two-directional alternatives that resulted in P values ≤ 0.05 were considered statistically significant.
RESULTS

Baseline Prevalence of Metabolic Syndrome.
The prevalence of MetS in baseline JHS participants is summarized in Table 1 . The overall (ages 21-94) prevalence of MetS in JHS cohort was 39.4%. Large percentages of participants with MetS were found to have elevated blood pressure (70.4%), abdominal obesity (64.6%), and low HDL-C concentration (37.2%). Among ages 35-84, the age-adjusted prevalence was 44.8% in women and 33.4% in men (P < 0.0001) ( Table 2 ). Women with MetS had comparatively higher prevalence of abdominal obesity and low HDL-C concentration than men (P < 0.0001 for both comparisons).
For the cohort as a whole, prevalence of elevated blood pressure, abdominal obesity, elevated triglyceride and glucose levels increased with age while low HDL-C concentration was about equally prevalent across all age groups. The prevalence of elevated triglyceride and low HDL-C were significantly higher in Smokers compared with nonsmokers. In addition, participants with higher educational attainment, house income and absence of alcohol consumption have lower prevalence of MetS, elevated blood pressure, abdominal obesity and elevated glucose levels. ( Table 2 ) Metabolic Syndrome and Prevalent CHD, CBD and CVD. The prevalence of CVD, CHD and CBD among those with MetS was 12.8%, 8.7% and 5.8%, respectively. In logistic regression analyses adjusted for age and sex, the MetS associated OR for prevalent CVD, CHD and CBD were about 1.7 ( Table  3) .
CONCLUSION
Prevalence of Metabolic Syndrome. The prevalence of the MetS reported by different studies in the United States has varied widely. Differences in the characteristics of study populations, the definition of the MetS, study geographic location and study time periods have all contributed to this variation. Data from population-based cohorts like Framingham Offspring Study and San Antonio Heart Study during the early to mid1990s reported high prevalence estimates (24% to 30%, respectively) among participants who did not have diabetes (12) . Baseline data (obtained 1987-1989 ) from the Atherosclerosis Risk in Communities Study indicated that the prevalence of MetS was 28% in African-American men, 18% in women and 30% overall in a middle-aged cohort (17) . During 1988-1994, the National Health and Nutrition Examination Survey study (NHANES III, a national probability sample) using NCEP/ATP III criteria, found that the unadjusted prevalence of MetS was 21.8% among US general population (11) . More recently, NHANES III, using consistent sampling methodology and case definition, found a prevalence of 26.7% in the year 2000 (18) . Increases in the prevalence of obesity and hypertension, and to a lesser degree hypertriglyceridemia and low HDL cholesterol concentration, most likely accounted for much of this increase (18) .
Our analyses of recently obtained (2000) (2001) (2002) (2003) (2004) baseline data from Jackson Heart Study, the largest population-based epidemiological study of CVD in African Americans ever undertaken, demonstrates extraordinarily high MetS prevalence and typical component profiles when compared to the general MetS literature. Among ages 35-84 the prevalence was 44.8% in women and 33.4% in men, far above corresponding national rates. The prevalence of MetS is significantly and inversely associated with socioeconomic status and is higher in women than in men at the similar degree of education and socioeconomic status. Both in men and women, the prevalence significantly decreases with increase in household income and educational attainment.
Although limited data are available regarding the prevalence of various MetS profiles in the African American population, our study suggests that African Americans may have distinct cardiometabolic risk patterns within the rubric of MetS. In studies examining differences in prevalence of MetS profiles, abdominal obesity, elevated blood pressure and elevated triglyceride predominated as MetS components in European and Mexican Americans (11, (19) (20) (21) (22) . Among JHS cohort, however, elevated blood pressure, abdominal obesity, and low HDL-C concentration were more frequent than the triad of conditions most commonly seen in MetS among other groups. The higher frequency of low HDL-C concentration is notable for at least two reasons. First, owing to a multitude of studies that have reported high HDL-C concentration for African Americans, there is a prevailing notion that low HDL-C concentration is relatively uncommon among AfricanAmericans (11, 23, 24) . However, NHANES highlighted that the race-specific rates of low HDL-C have risen among African Americans from 1989-1994 to 1999-2000 (11, 25) . Our data seem to reflect this trend. Second, the usual reciprocal elevation in triglyceride concentration that accompanies low HDL-C is not evident and the prevalence of low HDL-C level stays high across age spectra in our cohort. This finding seems to corroborate indirectly the findings of the Triglyceride and Cardiovascular Risk in African American (TARA) Study of the National Institutes of Health, which reported that insulin-resistant African-American subjects do not demonstrate impairment of post-heparinlipoprotein lipase (PH-LPL) activity commonly seen with insulin resistance in other ethnic groups. This impairment is inversely associated with serum triglyceride concentration (26) . A low frequency of impairment of PH-LPL in AA with metabolic syndrome (and presumed insulin resistance) would help explain why TG levels remain low, even in a population with high rates of depressed HDL-C levels. This could explain our observation that triglyceride concentration abnormalities contribute little to the prevalence of MetS in this African American cohort. In addition, it is worthy to note that the prevalence of MetS tends to be lower in current smokers; whose triglyceride level is elevated and HDL-C concentration is depressed. The alcohol drinking also had lower prevalence of MetS with decreased prevalence of low HDL-C concentration. These findings are generally consistent with the expected and widely replicated inverse association of HDL and smoking. The positive association of triglycerides and smoking has also been reported. In contrast, the lower prevalence of MetS in those who are not current drinkers suggests that drinking may have modest differential influences on the individual MetS components.
Recently, the concept of the MetS has been challenged on several fronts. Variation in its definition by different professional and scientific bodies (27) , ethnic specificity of some component cut-points (28) and the additive rather than synergistic impact of risk factors on CVD outcomes (29) have led to controversy in assigning the label "syndrome" to this grouping of metabolic abnormalities. NCEP-ATP III does not mandate any specific metabolic component as a necessary condition for the diagnosis of MetS. This is controversial, however, and data that suggest a common antecedent or underlying perturbation in metabolic function produces the syndrome has been reported (30) . In the JHS cohort, although elevated blood pressure, abdominal obesity and low HDL-C are particularly prevalent in MetS, the frequency of elevated glucose is still substantial both in men and women, indicating that hyperglycemia is also important contributors to MetS prevalence. This result is consistent with the fact that insulin resistance is the core pathology of the MetS (31), a notion further supported by other studies. (29) (32) . Metabolic Syndrome and CVD Disparities. Growing evidence for MetS as a major cause for both diabetes and CVD raises the question of whether differences in MetS prevalence and /or profiles between African and European Americans might help explain racial disparities in the prevalence of diabetes and cardiovascular complications. While our study does not permit a direct cross-racial comparison, the JHS cohort demonstrated a high prevalence of CHD, CBD and overall CVD, and the presence of MetS increased the odds of these diseases are substantially comparable to the over 1.6-fold increase in risk found by others (21, 23) . Our demonstration of high OR and higher prevalence suggest a high attributable risk in AA population for MetS. This further suggests that control/elimination of MetS would result in a substantial reduction in manifest CVD among AA.
We also found that the risk for CVD attributable to these cardiometabolic abnormalities is greater in women than in men. Recent mortality data from the San Antonio Heart Study demonstrated that the association between MetS and CVD death was more than twice as large in women as in men (33) . The authors suggested that a possible explanation for this difference is the stronger diabetes-CVD association in women. In JHS, increased prevalence of MetS in women was associated with their greater proportion of abdominal obesity and low HDL-C concentration. This could reflect sexspecific impact of obesity on glucose homeostasis, lipid profiles and atherosclerosis (34) . Limitations of study. The principal limitation of this analysis is the use of cross-sectional data, necessitated by the use of the initial data from this new cohort. Thus, causal pathways underlying the observed relationships can not be inferred. Also, owing to the design of the initial JHS Exam used for this analysis, we relied significantly, though not exclusively, on self-reported medical history data. While CBD history was obtained exclusively by self-report, the CHD definition (and consequently the CVD definition) combined self-reported data with ECG findings for corroboration and additional case ascertainment (e.g., "silent myocardial infarction"). Another limitation of this analysis is that we were not able to fully account for all potential covariates, such as changes in physical activity, dietary information and weight gain. Therefore, future research should investigate the impact of these covariates, especially dietary and fitness differences among the participants with or without metabolic syndrome.
While not a limitation specific to this analysis, it should be noted that the NCEP ATP-III cut-points for abnormal HDL and triglyceride concentration may lead to an underestimation of metabolic risk among African Americans. As noted above, at least one prior investigation indicated that African Americans, despite being more insulin resistant than European American counterparts, paradoxically exhibited lower triglyceride and higher HDL-C cholesterol concentration (35) .
This suggests that applying a uniform cut-point for both groups for triglyceride and HDL-C concentrations may result in significant misclassification (36) . Adjustment of cut-point values (using CVD incidence data by TG and HDL concentrations) or measures of lipoprotein subclass profiles (e.g., VLDL, small LDL, HDL particle concentrations) may provide better estimates of lipid-related metabolic risk in African Americans than using solely the lipid criteria from NCEP/ATP III 26 . However, our data affirms that abdominal obesity, elevated blood pressure and low HDL-C concentration are key components of MetS in African-American population. 
